Document Detail

Chronic hepatitis C: treatment comparison between 3 and 5 million units of interferon alpha-2b.
MedLine Citation:
PMID:  9883467     Owner:  NLM     Status:  MEDLINE    
Interferon (IFN) is the only drug that has been approved by the FDA for therapy of chronic hepatitis C. However, optimal dose and duration of therapy are still controversial. This study compares the effectiveness of treatment of chronic hepatitis C patients with 3 vs. 5 million units (MU) of recombinant alpha-interferon 2-b three times per week. We also evaluated the relapse rate with a shorter 12 week-course of therapy in those patients who had normalization of aminotransferases by week 12. Seventy-five patients were randomized to receive either 3 vs. 5 MU of IFN; seventy-two completed the study. A complete response was seen in 11/35 (31%) of those treated with 5 MU vs. 13/37 (35%) in the 3 MU dose (p = 0.74). Patients were followed after IFN was withdrawn and only 2 had persistently normal aminotransferases. Analysis of multiple variables was done to predict response to IFN and only elevations of GGT, ferritin and alkaline phosphatase were found to be predictors of a poor response. Therefore, we recommend initial therapy with 3 MU of IFN for a longer period than 12 weeks in patients who show a response.
F Castro; E A Torres; J Oharriz; C González-Keelan; C Pérez; C Rubio
Related Documents :
12895267 - Impact of high-dose interferon induction and ribavirin therapy in patients with chronic...
1386907 - A successful two-step integrated protocol of anti-hbv vaccination in chronic uremia.
2452337 - Intraventricular administration of interferon and administration of methisoprinol by mo...
20950477 - Serial interferon-gamma release assays during treatment of active tuberculosis in young...
16877907 - Respiratory outcome of midface advancement with distraction: a comparison between le fo...
15287307 - Le fort i miniplate osteosynthesis: a randomized, prospective study comparing resorbabl...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Puerto Rico health sciences journal     Volume:  17     ISSN:  0738-0658     ISO Abbreviation:  P R Health Sci J     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1999-02-05     Completed Date:  1999-02-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8303541     Medline TA:  P R Health Sci J     Country:  PUERTO RICO    
Other Details:
Languages:  eng     Pagination:  221-5     Citation Subset:  IM    
Department of Medicine, School of Public Health, University of Puerto Rico, San Juan, PR 00936-0350.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alkaline Phosphatase / blood
Antiviral Agents / administration & dosage*
Clinical Enzyme Tests
Ferritins / blood
Hepatitis C, Chronic / diagnosis,  therapy*
Interferon Alfa-2b / administration & dosage*
Middle Aged
Multivariate Analysis
Time Factors
Transaminases / blood
gamma-Glutamyltransferase / blood
Reg. No./Substance:
0/Antiviral Agents; 9007-73-2/Ferritins; 99210-65-8/Interferon Alfa-2b; EC; EC 2.6.1.-/Transaminases; EC Phosphatase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of gender in very old age: profiles of functioning and everyday life patterns.
Next Document:  Chronic and subacute subdural hematoma in the adult population. The Puerto Rico experience.